193 related articles for article (PubMed ID: 16281513)
1. [Long term survival results in advanced prostate cancer treated with combined androgen blockade].
Zhang SG; Wang YH; Ding Y; Wu Y
Zhonghua Nan Ke Xue; 2005 Oct; 11(10):770-1, 774. PubMed ID: 16281513
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
Ueno S; Namiki M; Fukagai T; Ehara H; Usami M; Akaza H
Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
Miyake H; Hara I; Eto H
BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
[TBL] [Abstract][Full Text] [Related]
4. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
5. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
6. Hormone therapy for locally advanced prostate cancer.
Fowler JE; Bigler SA; White PC; Duncan WL
J Urol; 2002 Aug; 168(2):546-9. PubMed ID: 12131306
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of 60 Gy conventional radiotherapy combined with androgen deprivation for localized or locally advanced prostate cancer.
Hashine K; Numata K; Azuma K; Sumiyoshi Y; Kataoka M
Jpn J Clin Oncol; 2005 Nov; 35(11):655-9. PubMed ID: 16275680
[TBL] [Abstract][Full Text] [Related]
8. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
10. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
11. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.
Akaza H; Homma Y; Usami M; Hirao Y; Tsushima T; Okada K; Yokoyama M; Ohashi Y; Aso Y;
BJU Int; 2006 Sep; 98(3):573-9. PubMed ID: 16925756
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up after triple treatment of prostate cancer stage pT3.
Schelin S; Madsen M; Palmqvist E; Mäkelä E; Klintenberg C; Aus G
Scand J Urol Nephrol; 2009; 43(3):186-91. PubMed ID: 19353383
[TBL] [Abstract][Full Text] [Related]
14. Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinoma.
Fowler JE; Bigler SA; Kolski JM; Yee DT
Cancer; 1998 Mar; 82(6):1112-7. PubMed ID: 9506357
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of the time to clinical endpoints for advanced prostate cancer.
Sharifi N; Dahut WL; Steinberg SM; Figg WD; Tarassoff C; Arlen P; Gulley JL
BJU Int; 2005 Nov; 96(7):985-9. PubMed ID: 16225513
[TBL] [Abstract][Full Text] [Related]
16. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
17. [Maximal androgen blockade and maximal androgen blockade combined with 125I brachytherapy for prostatic cancer].
Su Y; Yao MY; Yuan Z; Yang JJ; Liu J; Hu XN
Zhonghua Nan Ke Xue; 2003 Sep; 9(6):434-5. PubMed ID: 14574808
[TBL] [Abstract][Full Text] [Related]
18. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer.
McLeod DG; Iversen P; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2006 Feb; 97(2):247-54. PubMed ID: 16430622
[TBL] [Abstract][Full Text] [Related]
19. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
Ito T; Aizawa T; Yamamoto S; Ohkubo Y; Tsujino S; Miki M
Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression.
Lane TM; Ansell W; Farrugia D; Wilson P; Williams G; Chinegwundoh F; Philp T; Hines J; Oliver RT
Urol Int; 2004; 73(2):117-22. PubMed ID: 15331894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
